Clinical trial
Bevacizumab for Recurrent Malignant Glioma
NCT00271609 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00271609 |
|---|---|
| Title | Bevacizumab for Recurrent Malignant Glioma |
| Official title | A Phase II Trial of Bevacizumab for Patients With Recurrent High-Grade Gliomas |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent High-Grade Gliomas, Malignant Gliomas |
| Intervention type | Drug |
| Interventions | Bevacizumab |
| Enrollment | 88 |
| Start date | Dec 1, 2005 |
| Primary completion | Mar 1, 2011 |
| Completion | Feb 1, 2014 |
| First posted | Jan 2, 2006 |
| Last update posted | Apr 29, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: